Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 8/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PRCP | P42785 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4043644 | 0.86 | MAOA (0.46) | MAOADRD2TSHRHSD17B10KDM4E | |
| SCHEMBL18351805 | 0.73 | ALDH1A1 (0.36) | TSHRKDM4EALDH1A1PRCPGAA | |
| SCHEMBL31069871 | 0.73 | PRCP (0.61) | MAOADRD2TSHRHSD17B10KDM4E | |
| SCHEMBL29658050 | 0.73 | PRCP (0.61) | MAOADRD2TSHRHSD17B10KDM4E | |
| SCHEMBL29658057 | 0.73 | PRCP (0.61) | MAOADRD2TSHRHSD17B10KDM4E | |
| SCHEMBL1010378 | 0.73 | PRCP (0.61) | MAOADRD2TSHRHSD17B10KDM4E | |
| SCHEMBL1011611 | 0.73 | PRCP (0.61) | MAOADRD2TSHRHSD17B10KDM4E | |
| SCHEMBL327738 | 0.73 | PRCP (0.61) | MAOADRD2TSHRHSD17B10KDM4E | |
| SCHEMBL29658056 | 0.73 | PRCP (0.61) | MAOADRD2TSHRHSD17B10KDM4E | |
| SCHEMBL29384464 | 0.73 | PRCP (0.61) | MAOADRD2TSHRHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152177-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-06-17 | — | — | US | claimed |
| EP-1984351-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | Memory Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | claimed |
| WO-2007098418-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-08-30 | — | — | WO | claimed |
| US-20100152177-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-06-17 | — | — | US | disclosed |
| US-7696229-B2 | Compounds having 5-HT6 receptor affinity | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-04-13 | — | — | US | disclosed |
| EP-2162433-A2 | 4' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | Memory Pharmaceuticals Corporation (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20100029629-A1 | ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2010011546-A2 | ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-01-28 | — | — | WO | disclosed |
| EP-2121603-A2 | 6' SUBSTITUTED INDOLE AND INDAZOLE DERIVATIVES HAVING 5-HT6 RECEPTOR AFFINITY | Memory Pharmaceuticals Corporation (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080318941-A1 | 4' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-12-25 | — | — | US | disclosed |
| EP-1689393-A4 | PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-12-17 | — | — | EP | disclosed |
| WO-2008147812-A2 | 4' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-12-04 | — | — | WO | disclosed |
| EP-1984351-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | Memory Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | US | disclosed |
| WO-2008101247-A2 | 6 ' SUBSTITUTED INDOLE AND INDAZOLE DERIVATIVES HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080039462-A1 | Compounds having 5-HT6 receptor affinity | MEMORY PHARMACEUTICALS CORPORATION | 2008-02-14 | — | — | US | disclosed |
| WO-2007098418-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-08-30 | — | — | WO | disclosed |
| US-20070123561-A1 | Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors | LEE DENNIS | 2007-05-31 | — | — | US | disclosed |
| EP-1689393-A2 | PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005037198-A2 | PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152177-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR3B, HTR1B | MAOA 93/4885DRD2 18/4885TSHR 227/4885 |
| US-20080318941-A1 | 4' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR1B, HTR3B | MAOA 117/4885DRD2 18/4885TSHR 241/4885 |
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR1B, HTR1A | MAOA 95/4885DRD2 19/4885TSHR 219/4885 |
| US-20080039462-A1 | Compounds having 5-HT6 receptor affinity | HTR6, HTR3B, HTR1B | MAOA 93/4885DRD2 18/4885TSHR 227/4885 |
| US-20100029629-A1 | ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR1A, HTR5A | MAOA 134/4885DRD2 60/4885TSHR 243/4885 |
| US-20070123561-A1 | Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors | TNK2, CDC42BPB, CDC42BPA | MAOA 3003/4885DRD2 3405/4885TSHR 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.